DiaMedica Inc.
TSX VENTURE : DMA

DiaMedica Inc.

July 07, 2014 08:30 ET

DiaMedica Appoints Rich Pilnik as Chairman of the Board of Directors

MINNEAPOLIS, MINNESOTA--(Marketwired - July 7, 2014) - DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, announced today the appointment of Richard Pilnik as Chairman of the Company's Board of Directors.

Mr. Pilnik has been a member of DiaMedica's Board of Directors since 2009. He recently retired as Executive Vice President and President of Quintiles Commercial Solutions, a global pioneer in pharmaceutical services. Mr. Pilnik previously spent 25 years at Eli Lilly, where he held several leadership positions including Group Vice President and Chief Marketing Officer.

"Rich's vast background in the global biopharmaceutical market, healthcare services experience, and strategic planning and medical/marketing expertise will be a great complement in driving DiaMedica's product and corporate development," said Rick Pauls, President & CEO.

Mr. Pilnik will replace Rick Pauls as Chairman. Mr. Pauls will continue as President & CEO and a member of the Board of Directors.

"I am very pleased to accept the Chairmanship of the Board of DiaMedica and I look forward to helping the Company advance the development of new and innovative therapies and cultivating strategic relationships," said Mr. Pilnik.

Mr. Pilnik has served on the board of directors of Elan Corporation, a successful bio-pharmaceutical company focused on neurodegenerative diseases, prior to the company being acquired in 2013. He holds a Bachelor of Arts in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University.

About DiaMedica

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage product, DM199, is a recombinant human protein known as rhKLK1 that represents a novel approach to treating diabetes and associated complications. DiaMedica is also developing a novel monoclonal antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical development.

The Company is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, including the intended use of the net proceeds of the Offering, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in DiaMedica's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.

Contact Information